The triton clinical trial programme: Evaluation of the parp inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Authors
Category Primary study
ConferenceAsia-Pacific Journal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 5b3d042cdee88df863176f45760f1ed7e7384269
First added on: Apr 29, 2026